Its profit increased 15.5% to RON21.44 million in January-September, from RON18.56 million in the year-earlier period.
The company’s operating profit climbed to RON21.95 million in the first nine months, from RON18.51 million in the same interval the year before.
Biofarm’s portfolio includes some 200 products covering 60 therapeutic areas and ranks among Romania’s top ten drugmakers by volumes.
Biofarm is controlled by regional investment fund SIF Muntenia (SIF4.RO), with a 45.88% stake, while SIF Banat-Crisana (SIF1.RO) and SIF Moldova (SIF2.RO) each own nearly 18.9% and 13.8%, respectively.
On the Bucharest Stock Exchange Friday, Biofarm traded down 1.11%, at RON0.2774 a share.